Drug Prices
Commentary
Tying U.S. Drug Prices To Foreign Markets Risks Innovation And Lives
Earlier this month, President Donald Trump signed what he called “one of the most consequential Executive Orders in our Country’s history.” The order is essentially an updated version of his administration’s 2020 “Most Favored Nation” policy. It directs pharmaceutical companies to tie the U.S. prices of their drugs to the ...
Blog
Don’t Take Cutting-Edge Drugs for Granted
It’s hard to imagine a more destructive plan. Importing foreign price controls on prescription drugs would reduce access to existing treatments for everything from rare diseases to cancer. To understand why, consider two recent pieces by Michael Baker for the American Action Forum’s “Reality Check-Up: The Truth About Single-Payer Systems.” ...
Commentary
Trump’s ‘Most Favored Nation’ Drug Plan Doesn’t Favor Americans
Last week, President Donald Trump revived one of the most ill-conceived health policy ideas of his first term. Via a new executive order, he’s directed his administration to deliver “most-favored-nation prescription drug pricing to American patients.” The idea is to bring other developed countries’ lower drug prices to the United ...
Blog
Read the latest on the push for drug price controls
To Improve Drug Affordability Congress Should Fix the Payment System
Demanding that drug prices in the U.S. equal overseas prices is akin to demanding that the price of all expensive handbags should equal the prices for the knockoffs that people purchase from street vendors. Of course knockoff bags are cheaper. They violate the intellectual property rights of the bag’s maker, ...
Commentary
Trump Should Support Effective Drug Policy Reforms Not The MFN Gimmick
The Trump Administration has announced its desire to impose price controls on drugs – officially called a most favored nation (MFN) policy. Essentially, the policy sets the price for the targeted drugs at the lowest price in other industrialized countries. The president’s justification for the MFN is simple: Americans are ...
Blog
Read about the push for drug price controls
Trump and Biden Agree on Drug Pricing
Patients will pay dearly, as Michael Baker and Douglas Holtz-Eakin explain in two recent pieces for the American Action Forum’s “Reality Check-Up: The Truth About Single-Payer Systems. Biden signed the Inflation Reduction Act into law in 2022. It directs the feds to “negotiate” prices for a steadily increasing number of ...
Commentary
Direct-To-Consumer Ozempic Sales Are A Win For Patients And Drug Makers
Google Wegovy. Or Zepbound. The search results offer a preview of a direct-to-consumer future for prescription drugs. The brand-name drugs’ homepages generally get top billing. But not far down are ads for telehealth companies promising access to the drugs or others with the same active pharmaceutical ingredient, or API, without ...
Commentary
A Most Flawed Notion: Medicaid ‘Fix’ Will Worsen 340B Crisis
Congressional Republicans are under pressure to find savings to make the math in their budget reconciliation package add up. Medicaid, which accounts for just under 10% of federal spending, has become an obvious target. But instead of addressing the flawed incentives driving the program’s unsustainability, the Trump administration is pushing ...
Commentary
Insurers, bureaucrats shouldn’t deprive patients of lifesaving treatments
Imagine being told there’s a drug that might save your life — but your insurance won’t cover it for 18 months. That’s the reality for patients under a new policy from Independence Blue Cross, a Philadelphia-based insurer. The insurer announced earlier this year that it will delay coverage of therapies ...
Drug Importation
Pipes: “Imposing tariffs on pharmaceutical products and ingredients would be a grave mistake”
Click here to download a copy of Pipes’ comments Thank you for inviting public input on the Department’s Section 232 examination of pharmaceutical imports and their relevance to U.S. national security interests. As president and CEO of the Pacific Research Institute and a longtime healthcare policy analyst, I’ve spent over ...
Tying U.S. Drug Prices To Foreign Markets Risks Innovation And Lives
Earlier this month, President Donald Trump signed what he called “one of the most consequential Executive Orders in our Country’s history.” The order is essentially an updated version of his administration’s 2020 “Most Favored Nation” policy. It directs pharmaceutical companies to tie the U.S. prices of their drugs to the ...
Don’t Take Cutting-Edge Drugs for Granted
It’s hard to imagine a more destructive plan. Importing foreign price controls on prescription drugs would reduce access to existing treatments for everything from rare diseases to cancer. To understand why, consider two recent pieces by Michael Baker for the American Action Forum’s “Reality Check-Up: The Truth About Single-Payer Systems.” ...
Trump’s ‘Most Favored Nation’ Drug Plan Doesn’t Favor Americans
Last week, President Donald Trump revived one of the most ill-conceived health policy ideas of his first term. Via a new executive order, he’s directed his administration to deliver “most-favored-nation prescription drug pricing to American patients.” The idea is to bring other developed countries’ lower drug prices to the United ...
Read the latest on the push for drug price controls
To Improve Drug Affordability Congress Should Fix the Payment System
Demanding that drug prices in the U.S. equal overseas prices is akin to demanding that the price of all expensive handbags should equal the prices for the knockoffs that people purchase from street vendors. Of course knockoff bags are cheaper. They violate the intellectual property rights of the bag’s maker, ...
Trump Should Support Effective Drug Policy Reforms Not The MFN Gimmick
The Trump Administration has announced its desire to impose price controls on drugs – officially called a most favored nation (MFN) policy. Essentially, the policy sets the price for the targeted drugs at the lowest price in other industrialized countries. The president’s justification for the MFN is simple: Americans are ...
Read about the push for drug price controls
Trump and Biden Agree on Drug Pricing
Patients will pay dearly, as Michael Baker and Douglas Holtz-Eakin explain in two recent pieces for the American Action Forum’s “Reality Check-Up: The Truth About Single-Payer Systems. Biden signed the Inflation Reduction Act into law in 2022. It directs the feds to “negotiate” prices for a steadily increasing number of ...
Direct-To-Consumer Ozempic Sales Are A Win For Patients And Drug Makers
Google Wegovy. Or Zepbound. The search results offer a preview of a direct-to-consumer future for prescription drugs. The brand-name drugs’ homepages generally get top billing. But not far down are ads for telehealth companies promising access to the drugs or others with the same active pharmaceutical ingredient, or API, without ...
A Most Flawed Notion: Medicaid ‘Fix’ Will Worsen 340B Crisis
Congressional Republicans are under pressure to find savings to make the math in their budget reconciliation package add up. Medicaid, which accounts for just under 10% of federal spending, has become an obvious target. But instead of addressing the flawed incentives driving the program’s unsustainability, the Trump administration is pushing ...
Insurers, bureaucrats shouldn’t deprive patients of lifesaving treatments
Imagine being told there’s a drug that might save your life — but your insurance won’t cover it for 18 months. That’s the reality for patients under a new policy from Independence Blue Cross, a Philadelphia-based insurer. The insurer announced earlier this year that it will delay coverage of therapies ...
Pipes: “Imposing tariffs on pharmaceutical products and ingredients would be a grave mistake”
Click here to download a copy of Pipes’ comments Thank you for inviting public input on the Department’s Section 232 examination of pharmaceutical imports and their relevance to U.S. national security interests. As president and CEO of the Pacific Research Institute and a longtime healthcare policy analyst, I’ve spent over ...
